Waninger, J.J.; Fecher, L.A.; Lao, C.; Yentz, S.; Green, M.D.; Demirci, H.
Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma. Cancers 2022, 14, 5789.
https://doi.org/10.3390/cancers14235789
AMA Style
Waninger JJ, Fecher LA, Lao C, Yentz S, Green MD, Demirci H.
Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma. Cancers. 2022; 14(23):5789.
https://doi.org/10.3390/cancers14235789
Chicago/Turabian Style
Waninger, Jessica J., Leslie A. Fecher, Christopher Lao, Sarah Yentz, Michael D. Green, and Hakan Demirci.
2022. "Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma" Cancers 14, no. 23: 5789.
https://doi.org/10.3390/cancers14235789
APA Style
Waninger, J. J., Fecher, L. A., Lao, C., Yentz, S., Green, M. D., & Demirci, H.
(2022). Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma. Cancers, 14(23), 5789.
https://doi.org/10.3390/cancers14235789